These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 28395288)

  • 1. Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma.
    Klein J; Juratli TA; Radev Y; Daubner D; Soucek S; Schackert G; Krex D
    Oncology; 2017; 93(1):43-50. PubMed ID: 28395288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
    Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
    Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series.
    Subach BR; Witham TF; Kondziolka D; Lunsford LD; Bozik M; Schiff D
    Neurosurgery; 1999 Jul; 45(1):17-22; discussion 22-3. PubMed ID: 10414561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
    Samis Zella MA; Wallocha M; Slotty PJ; Isik G; Hänggi D; Schroeteler J; Ewelt C; Steiger HJ; Sabel M
    Acta Neurochir (Wien); 2014 Feb; 156(2):313-23. PubMed ID: 24287680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.
    Della Puppa A; Lombardi G; Rossetto M; Rustemi O; Berti F; Cecchin D; Gardiman MP; Rolma G; Persano L; Zagonel V; Scienza R
    J Neurooncol; 2017 Jan; 131(2):331-340. PubMed ID: 27757721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric drug delivery for the treatment of glioblastoma.
    Wait SD; Prabhu RS; Burri SH; Atkins TG; Asher AL
    Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii9-ii23. PubMed ID: 25746091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.
    Giese A; Kucinski T; Knopp U; Goldbrunner R; Hamel W; Mehdorn HM; Tonn JC; Hilt D; Westphal M
    J Neurooncol; 2004 Feb; 66(3):351-60. PubMed ID: 15015668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
    Attenello FJ; Mukherjee D; Datoo G; McGirt MJ; Bohan E; Weingart JD; Olivi A; Quinones-Hinojosa A; Brem H
    Ann Surg Oncol; 2008 Oct; 15(10):2887-93. PubMed ID: 18636295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A Case of Symptomatic Cyst Formation after BCNU Wafer Implantation for Glioblastoma].
    Nakase K; Matsuda R; Nishimura F; Nakamura M; Motoyama Y; Park YS; Nakase H
    No Shinkei Geka; 2015 Aug; 43(8):747-52. PubMed ID: 26224470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
    Pallud J; Audureau E; Noel G; Corns R; Lechapt-Zalcman E; Duntze J; Pavlov V; Guyotat J; Hieu PD; Le Reste PJ; Faillot T; Litre CF; Desse N; Petit A; Emery E; Voirin J; Peltier J; Caire F; Vignes JR; Barat JL; Langlois O; Dezamis E; Parraga E; Zanello M; Nader E; Lefranc M; Bauchet L; Devaux B; Menei P; Metellus P;
    Neuro Oncol; 2015 Dec; 17(12):1609-19. PubMed ID: 26185110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Recurrence After Resection of Malignant Gliomas With BCNU Wafer Implants: Retrospective Review in a Single Institution.
    Shimato S; Nishizawa T; Ohshima T; Imai T; Goto S; Yamamoto T; Kato K
    World Neurosurg; 2016 Jun; 90():340-347. PubMed ID: 26960286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
    Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
    World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series.
    Della Puppa A; Rossetto M; Ciccarino P; Denaro L; Rotilio A; d'Avella D; Scienza R
    World Neurosurg; 2011; 76(1-2):156-9; discussion 67-8. PubMed ID: 21839967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
    Noël G; Schott R; Froelich S; Gaub MP; Boyer P; Fischer-Lokou D; Dufour P; Kehrli P; Maitrot D
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):749-55. PubMed ID: 21300471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
    Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
    J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review.
    Zhang YD; Dai RY; Chen Z; Zhang YH; He XZ; Zhou J
    Turk Neurosurg; 2014; 24(5):639-45. PubMed ID: 25269031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
    Westphal M; Hilt DC; Bortey E; Delavault P; Olivares R; Warnke PC; Whittle IR; Jääskeläinen J; Ram Z
    Neuro Oncol; 2003 Apr; 5(2):79-88. PubMed ID: 12672279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.
    Xing WK; Shao C; Qi ZY; Yang C; Wang Z
    Drug Des Devel Ther; 2015; 9():3341-8. PubMed ID: 26170620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.